天美传媒

His role as a Clinical Professor of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Professor of Medicine and Director of Early Phase Clinical Trials Program in the Department of Medicine at Roswell Park Comprehensive Cancer Center, He is developing novel therapies for patients with cancer. This includes clinical trials from the early pre-clinical phase through phase I/II/III with emphasis on a combination of immune and targeted agents, novel drug design, including histology-agnostic trial development of targeted therapies. He also provides advice on regulatory requirements and necessary steps associated with advancing drugs, devices, and imaging agents toward clinical trials in patients. In his professional career, I have focused both on developing precision medicine agents as well as immunotherapies. In the first-in-human trial of PLX4032/vemurafenib, our team has provided critical PK/PD data that led to the first in class/ first in human FDA-approved BRAF inhibitor. His interest and expertise in immunotherapy started in the early 1990s with animal models of IL-2 and IL-15 cytokines and natural killer cell development, continued with high dose IL-2 studies, and subsequently Phase I-III trials with both CTLA-4 and PD1/PDL-1 checkpoint inhibitors. Our team was instrumental in the development of talimogene laherparepvec, the first in human oncolytic virus therapy for patients with melanoma. Recently, we have explored immunotherapy combinations with targeted agents as well as combinations of oncolytic viruses with checkpoint inhibitors. Our work was instrumental in several FDA approvals of breakthrough anti-cancer drugs (vemurafenib, dabrafenib+trametinib, vemurafenib+cobimetinib, pembrolizumab, talimogene laherparepvec) and resulted in almost 100 manuscripts, including New England Journal of Medicine, Lancet, Journal of Clinical Oncology, JAMA, Nature. I am a member of American Society of Medical Oncology, Society of Immunotherapy in Cancer, ACP, AACR and Society of Melanoma Research and serve as an editor and reviewer for several peer reviewed journals.

Vadim Gushchin, M.D., serves as Director of The Melanoma and Skin Cancer Center at Mercy as well as Director of Gastrointestinal Oncology, a division of Surgical Oncology at Mercy Medical Center in Baltimore, Maryland. Dr. Gushchin offers expertise in complex malignancies and is a skilled cancer surgeon. He is exceptionally accomplished in minimally invasive surgery – most notably in da Vinci Robotic Surgery – as well as in traditional open surgery techniques. Gastrointestinal Cancer (GI Cancers), melanoma – more commonly known as skin cancer, and thyroid cancer are among the many cancer diagnoses Dr. Gushchin treats. To determine the best treatment option for his surgical oncology patients, Dr. Gushchin carefully evaluates each patient’s risk factors, medical history, current clinical condition, surgical alternatives and post-surgical recovery options in order to fully develop a thorough, personalized care plan. Dr. Gushchin comforts and compassionately walks his patients through the treatment steps needed to care for melanoma, thyroid and parathyroid disease, peritoneal surface malignancies (abdominal tumors), and recurring tumors within the colon, rectum and liver. Dr. Gushchin is well-recognized for his experience in treating complex cancers with HIPEC (Hyperthermic Intraperitoneal Chemotherapy). Dr. Gushchin trained under the internationally renowned surgical oncologist Dr. Paul Sugarbaker to master this procedure, which involves cytoreductive surgery followed by a heated chemotherapy solution to reduce and eliminate tumors. Dr. Gushchin has participated in over 150 HIPEC surgeries and provides patients expertise in complicated HIPEC surgeries including repeat HIPEC surgeries, simultaneous liver resections at the time of HIPEC as well as other advanced surgical treatments in conjunction with HIPEC treatment. An international presenter and teacher, Dr. Gushchin has educated physicians around the world on HIPEC treatment and has organized teaching courses for the treatment of peritoneal surface malignancies (complex abdominal cancers that can be treated with HIPEC). As an extension of his knowledge and compassion, Dr. Gushchin has been instrumental in setting up treatment centers for peritoneal surface malignancies in other parts of the world including Lithuania, Siberia and Ukraine. Dr. Vadim Gushchin is one of Mercy Medical Center’s top surgical oncologists. He utilizes many of the latest innovations in technology and research to provide state-of-the-art treatment options to his patients. Dr. Gushchin brings expertise in robotic surgery, using the da Vinci robot. Patients who qualify for da Vinci robot surgery typically experience the benefits of a more precise and exacting surgery, a less invasive procedure, shorter hospital stay and faster recovery. Dr. Vadim Gushchin leads a multidisciplinary team of experts at The Melanoma and Skin Cancer Center at Mercy to treat a wide range of skin cancers. As an experienced oncology surgeon and talented cancer specialist, he uses the Isolated Limb Infusion technique to try to save an arm or leg that has been aggressively attacked by skin cancer. Isolated Limb Infusion, also known as ILI, offers patients a remarkable alternative approach to metastatic melanoma on a limb. This type of skin cancer commonly leads to amputation or a disfiguring result. Dr. Gushchin and his patients know this doesn’t always have to be the case. Isolated Limb Infusion gives Dr. Gushchin a fighting chance to save his patients’ affected arms and/or legs, reduce or shrink the cancerous tumor and avoid the need for a more radical surgery.

Dr. Lynn Dengel is a board-certified and fellowship-trained surgical oncologist specializing in breast cancer and melanoma. She is an Assistant Professor in the Division of Surgical Oncology at the University of Virginia and practices as a breast and melanoma surgeon at Sentara Martha Jefferson Hospital in Charlottesville, Virginia. Dr. Dengel cares for patients in a robust multidisciplinary fashion, utilizes state of the art technology, incorporates up-to-date research findings and takes time to provide education and counseling to her patients to provide outstanding clinical care. Dr. Dengel is recognized by her peers as an expert in breast disease and melanoma. She serves as a committee member for both the Society of Surgical Oncology and the American Society of Breast Surgeons. She has authored and co-authored several articles in leading peer-reviewed publications, including the Annals of Surgical Oncology, Journal of Clinical Oncology, and Annals of Surgery. Dr. Dengel has received recognition for her outstanding research, including the Conquer Cancer Foundation of ASCO Merit Award, supported by Susan G. Komen for the Cure, and the Harvey Baker Traveling Fellow Award from the Society of Surgical Oncology. Research expertise: Dr. Dengel’s research and expertise include translational studies and clinical trials investigating the immune environment at tumor sites and mechanisms that may bolster innate immune response. She is the Principal Investigator of a clinical trial investigating focused ultrasound ablation combined with immunotherapy in advanced solid tumors. Dr. Dengel also serves as lead investigator in multiple studies investigating patient decision making, specifically aiming to improve the process of shared decision making and decreasing decisional regret for patients considering prophylactic mastectomy. Training and education: Dr. Dengel completed a breast surgery fellowship at Memorial Sloan Kettering Cancer Center in New York after finishing her general surgery residency at the University of Virginia Hospital Medical Center in Charlottesville, VA, where she received the Award of Academic Excellence from the department of surgery. Dr. Dengel received her medical degree from the Georgetown University School of Medicine in Washington D.C. where she graduated cum laude and was elected to the Alpha Omega Alpha medical honor society. Prior to medical school, she received her undergraduate degree from Dartmouth College.

Dr. Mario Sznol is a Professor of Medicine (Medical Oncology). Dr. Sznol, formerly with the National Cancer Institute, has an international reputation in cancer drug development. Dr. Sznol's expertise and experience is in cancer immunotherapy, drug development for cancer, and treatment of patients with melanoma and renal cell carcinoma. He is working to expand the opportunities for clinical trials at the Yale Cancer Center, particularly those focusing on immunotherapy and novel agents.

Education & Training:
Fellow-Mount Sinai College of Medicine (1987)
Resident-Baylor College of Medicine (1985)
MD-Baylor College of Medicine (1982)
BA-Rice University (1979)

Dr. Kluger is a medical oncologist who sees patients with melanoma and renal cell carcinoma. Her research interests focus on developing new drug regimens and biomarkers predictive of response to therapies in melanoma and renal cell carcinoma. She participates in a number of clinical trials studying new agents for the treatment of these diseases, both targeting the immune system and the cancer cell. She runs an active research laboratory that studies tumor and immune cells from patients treated with novel therapies to determine mechanisms of resistance to therapy and mediators of toxicity from immune checkpoint inhibitors. The laboratory also conducts pre-clinical studies to improve treatment regimens for patients with melanoma, renal cell carcinoma or brain metastasis.
Please visit the lab website at:
https://sites.google.com/yale.edu/hklugerlab/home?authuser=3

Education & Training:
Fellow-Yale University School of Medicine (2002)
Resident-University of New Mexico (1995)
MD-Tel Aviv University (1993)

Academic Director, Mohs and Dermatologic Surgery CenterDirector, High-Risk Skin Cancer Clinic, Dana-Farber Brigham Cancer Center Director, Micrographic Surgery and Dermatologic Oncology Fellowship Program
Associate Professor of Dermatology, Harvard Medical School







Leadership Title

Academic Director, Mohs and Dermatologic Surgery Center
Director, High-Risk Skin Cancer Clinic, Dana-Farber Brigham Cancer Center
Program Director, Micrographic Surgery and Dermatologic Oncology Fellowship Program


 

Specialties
Dermatology



Clinical Interests

Basal Cell Carcinoma
Cutaneous Oncology (Skin Cancer)
Dermatologic Oncology
Melanoma
Mohs Surgery
Non-Melanoma Skin Cancer
Public Health
Squamous Cell Carcinoma











 
Education





Internship
New York University Langone Medical Center, 2010 - 2011

 

Medical School
New York University School of Medicine, 2006 - 2010

 

Residency
Albert Einstein College of Medicine, 2011 - 2014



Board Certifications
Dermatology, 2014
Micrographic Dermatologic Surgery, 2021

Ann W. Silk is a medical oncologist at Dana-Farber Cancer Institute. Ann does research in Clinical Immunology and Oncology with a specialty in Merkel cell carcinoma and other non-melanoma skin cancers. Her research interests are intratumoral oncolytic viral therapy, IL-2 therapy, macrophage directed therapy, cancer vaccines, and brain metastases.

 






Physician

Co-Director of the Merkel Cell Carcinoma Center of Excellence
Physician
Assistant Professor of Medicine, Harvard Medical School
 



Centers/Programs














 
Diseases Treated


















 
Board Certification


Internal Medicine, 2011
Medical Oncology, 2014




 
Fellowship


University of Michigan Health System




 
Residency


University of Pittsburgh Medical Center




 
Medical School


University of Pittsburgh School of Medicine

Director, Mohs and Dermatologic Surgery Center Brigham and Women's Faulkner Hospital, Director, Mohs Surgery, VA Boston Healthcare System
Assistant Professor, Harvard Medical School
Dermatology

 







Leadership Title

Director, Mohs and Dermatologic Surgery Center
Director, Mohs Surgery, VA Boston Healthcare System


 

Specialties
Dermatology



Clinical Interests

Basal Cell Carcinoma
Cosmetic Dermatology
Cutaneous Oncology (Skin Cancer)
Laser And Cosmetic Surgery
Melanoma
Mohs Surgery
Non-Melanoma Skin Cancer
Squamous Cell Carcinoma












 
Education

Internship
Memorial Sloan Kettering Cancer Center, 2011 - 2012

 

Medical School
Yale University School of Medicine, 2006 - 2011

 

Residency
Yale New Haven Hospital, 2012 - 2015



Board Certifications
Dermatology, 2015
Micrographic Dermatologic Surgery, 2021



Fellowship
Northwestern University Feinberg School of Medicine, 2015 - 2016

---